Close this search box.

What’s rarer than a rare disease?  The controversial Institute for Clinical and Economic Review deciding that a drug to treat a rare disease meets the organization’s definition of value.

A recent report points out that ICER – the Boston-based drug price analysis group – did not give a “high value” rating to a single rare disease drug between 2014 and 2018.  Why? In, “Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies,” the independent Pioneer Institute suggests that ICER’s approach has fundamental flaws.  

In particular, the think tank argues that:

The paper sets out to determine whether “European style cost-effectiveness reviews” like ICER’s make sense for orphan drugs in the United States.  The unequivocal answer, the paper concludes, is: No.

Leave a Reply

Your email address will not be published. Required fields are marked *